Novo Nordisk ( NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its ...

The two main ingredients in this drug cannot be dissolved together, so it must be administered by an injection device with two chambers. Novo Nordisk’s manufacturing capacity for CagriSema is ...

Bristol Myers Squibb said it will acquire its struggling CAR-T partner 2Seventy Bio for $286 million, or $102 million net of ...

"Recall that CagriSema is more difficult to manufacture than tirzepatide due to its dual-chamber device, and NVO's future manufacturing capacity is TBD," wrote Leerink Partners analyst David ...

U.S. stock futures fall as President Donald Trump doesn't rule out a recession, and Oracle is set to report fiscal third-quarter results after the closing bell. Here's what investors need to know ...

Novo Nordisk stock tumbled Monday after its experimental weight-loss drug failed to top its rival from Eli Lilly in a Phase 3 study.

The Danish drugmaker's tests for CagriSema in patients with type 2 diabetes ... Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage ...

Against a backdrop of manufacturing prioritisation, Novo Nordisk’s contract with Swiss medical technology Ypsomed could include the supply of injection pens for CagriSema, the former’s ...

of a single-use pen device. BioChaperone® CagriSema is expected to offer significant manufacturing advantages, such as enabling it to be included in existing multi-use pen platforms, allowing for ...

Among our top detractors were Advanced Micro Devices (AMD), Novo Nordisk and ... weight loss results for its highly anticipated CagriSema product (22.7% actual weight loss versus expectations ...